Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Diabetes increases stent surgery risks

Written by | 8 Dec 2025

Patients with diabetes have an increased risk of complications after stent implantation, according to a study from Karolinska Institutet in Sweden published in Diabetes Care. The study emphasises… read more.

Oral GLP-1 drug shows promise for adults with diabetes and obesity

Written by | 25 Nov 2025

Orforglipron , an investigative and oral GLP-1 drug, appears to enable adults with obesity and Type 2 diabetes to achieve significantly more weight loss and improvement in blood… read more.

GLP-1 agonists: Addressing side effects of weight loss drugs

Written by | 24 Nov 2025

New research is uncovering how medications targeting the glucagon-like peptide-1 (GLP-1) system affect brain circuits involved in nausea, thirst, and pleasurable behaviors. These findings will be presented at… read more.

Why your daily walk might not work as well if you’re on metformin

Written by | 18 Nov 2025

A widely prescribed diabetes drug may be sabotaging one of the most trusted strategies for preventing the disease: exercise. That is the conclusion of a Rutgers-led study published in The Journal… read more.

UH pharmacy researcher provides new hope in managing diabetic ketoacidosis

Written by | 9 Nov 2025

A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels in diabetic patients and increasing exercise capacity for better health… read more.

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program

Written by | 31 Oct 2025

Nearly one-third of people with type 2 diabetes (T2D) in an Indian cohort achieved remission through an intensive lifestyle intervention program, according to a new study publishing October… read more.

Tzield accepted for expedited review by FDA for stage 3 type 1 diabetes through Commissioner’s National Priority Voucher pilot program – Sanofi

Written by | 28 Oct 2025

The FDA has accepted for expedited review the supplemental biologics license application (sBLA) for Tzield (teplizumab-mzwv) to delay the progression of stage 3 type 1 diabetes (T1D) in… read more.

Semaglutide provides powerful protection against diabetic retinopathy, the leading cause of blindness in working-age adults, Greek study suggests

Written by | 24 Sep 2025

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting… read more.

Nearly half of those with diabetes unaware they have the disease

Written by | 13 Sep 2025

A large portion of the global population with diabetes remains undiagnosed or is not receiving optimal care, according to a new study published in The Lancet Diabetes & Endocrinology. The Institute… read more.

The human touch of doctors will still be needed in the AI healthcare revolution, technology expert suggests

Written by | 6 Aug 2025

AI-based medicine will revolutionise care including for Alzheimer’s and diabetes, predicts a technology expert, but it must be accessible to all patients. Healing with Artificial Intelligence, written by technology… read more.

AI model detects hidden diabetes risk by reading glucose spikes

Written by | 2 Aug 2025

To diagnose either type 2 diabetes or pre-diabetes, clinicians typically rely on a lab value known as HbA1c. This test captures a person’s average blood glucose levels over… read more.

GLP-1 RAs reduce dementia risks more than metformin

Written by | 26 Jul 2025

Researchers report that treatment of type 2 diabetes with glucagon- like peptide- 1 receptor agonists (GLP- 1 RAs) more effectively reduces the subsequent risk of dementia than treatment… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.